Please login to the form below

Not currently logged in
Email:
Password:

Genentech

This page shows the latest Genentech news and features for those working in and with pharma, biotech and healthcare.

AZ says dropping MedImmune will help ‘streamline’ its R&D

AZ says dropping MedImmune will help ‘streamline’ its R&D

Nevertheless, as MedImmune has operated as a semi-independent unit within AZ – in much the same way as Genentech within Roche and Sanofi’s Genzyme – the decision raises questions about how

Latest news

  • Alector kicks off next wave of biotech IPOs Alector kicks off next wave of biotech IPOs

    Arnon Rosenthal. Arnon Rosenthal, an ex-Genentech researcher, is the company’s co-founder and chief executive, and says its discovery platform combination of insights from human genetics and immunology can

  • Hardy returns to Genentech as CEO Hardy returns to Genentech as CEO

    In other news, Vertex fires chief operating officer. A familiar face is set to return to Genentech after the company announced that it has found a new chief executive officer. ... I look forward to seeing Genentech’s scientific excellence, employee

  • GSK and Sanofi join Finland's 500,000 genomics study GSK and Sanofi join Finland's 500,000 genomics study

    Service. It also has seven other pharmaceutical companies on board, including Biogen, AbbVie, Celgene, Genentech, Pfizer, MSD and AstraZeneca.

  • AZ’s Sean Bohen to exit after business overhaul; report AZ’s Sean Bohen to exit after business overhaul; report

    Sean Bohen, chief medical officer, AZ. Bohen joined AZ in 2015, coming from Roche’s Genentech unit where he was senior vice president of early development, and he is the fourth

  • Roche's O’Day swaps big pharma for big biotech Roche's O’Day swaps big pharma for big biotech

    Move to Gilead enforces reshuffle at neighbours Genentech. Gilead has selected Daniel O'Day, the current chief executive of Roche's pharma business, to take over as its CEO from 1 ... The move means Genentech will be looking for its fifth CEO in less

More from news
Approximately 7 fully matching, plus 228 partially matching documents found.

Latest Intelligence

  • 30 Women Leaders in UK Healthcare (part 2) 30 Women Leaders in UK Healthcare (part 2)

    The strategic partnerships she has forged on Immunocore’s behalf with big pharma  companies have secured vital funding and allowed the company to grow – AstraZeneca, Genentech and GlaxoSmithKline have each signed

  • Tackling the challenge of non-adherence Tackling the challenge of non-adherence

    A 2016 Best Practices LLC survey of leading drug manufacturers including Genentech Baxter BioScience, GlaxoSmithKline, Boehringer Ingelheim and Teva Pharmaceutical Industries revealed that 40% already have a dedicated big data group.

  • Deal Watch - May 2017 Deal Watch - May 2017

    Peptidream has something going for it apart from speculative numbers.  It has signed deals with 10 companies in the last two years including Novartis, Genentech, Sanofi, Merck &Co and Lilly.  The

  • Holding on to hope for Alzheimer’s advances Holding on to hope for Alzheimer’s advances

    Positive results from a phase Ib dose-escalation study were presented and Roche’s Genentech unit is pushing on with its 60 mg/kg dose in a phase III trial of

  • Deal Watch September 2016 Deal Watch September 2016

    Genentech will provide an $80m upfront payment, up to $830m in milestone fees plus royalties on net sales. . ... 1, 000+. Hanmi / Genentech. Licence. HM95573, a selective fibrosarcoma (RAF) kinase inhibitor targeting solid tumours.

More from intelligence
Approximately 0 fully matching, plus 25 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 26 partially matching documents found.

Latest from PMHub

  • Augmented Reality in patient communication – don’t miss out!

    Electronic Informed Consent Forms (e-ICFs) and Electronic Data Capture (EDC). In a recent well written article, Pierre Corin from Genentech discussed the drivers, advantages and possible challenges of using electronic ... References:. Pierre Corin,

  • It's time to change the conversation

    Changing the conversation with patients. One of the earliest adopters of technology and social media to change the conversation with patients, was Genentech. ... Starting from the position of caring about the patient, Genentech created the Herceptin

  • Top 7 Trends in Pharma Marketing for 2015

    Investment and utilisation of this tool is a trend that we expect to grow even more during 2015. Indeed, early Jan 2015 news that  Genentech, a member of the Roche Group,

  • Random42 Scientific Communication

    Genentech. Genzyme. Gilead. Grunenthal. GlaxoSmithKline. HCA Healthcare. Heron Therapeutics. Ignyta. Ironwood.

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics